Hormone Therapy Bone Density: The 69% Difference
A patient came to me last year after a bone density scan flagged early bone loss at 54. Her gynecologist had never mentioned hormone therapy bone density protection as an option. Not once, in the ten years since her periods stopped. Instead, her doctor told her to take calcium and walk more, and the hormone therapy bone density conversation never happened.
That silence is not unusual, and a new study makes it harder to justify. Researchers presented data at the Endocrine Society’s ENDO 2026 meeting. Women using menopausal hormone therapy had a 69% lower risk of low bone mineral density compared with women who were not using it. That is not a marginal benefit. That is one of the largest protective effects I have seen reported for a single, modifiable treatment in bone health.
I’ve had this conversation more times than I can count. Women assume hormone therapy is only about hot flashes. So once their hot flashes ease up, or never bothered them much, nobody brings it up again. Meanwhile, their bones keep losing density every single year estrogen stays low.
What the Hormone Therapy Bone Density Study Found
Diego Espinoza-Peralta and colleagues presented a retrospective cohort study at ENDO 2026, the Endocrine Society’s annual meeting, in June 2026. The study reviewed DXA bone scans from 387 women past menopause, comparing outcomes between hormone therapy users and nonusers.
Here’s what they found: women using hormone therapy had a 69% lower risk of low bone mineral density than women who were not using it. Their bone density ran higher specifically at the lumbar spine and total hip. Only about a third of the women in the study were using hormone therapy at all.
Translation: two out of three women in this study were going without a treatment that could be protecting their skeleton. And nobody had connected that dot for most of them. Bone loss has no symptoms until a fracture happens. So this is exactly the kind of protective effect that gets missed until it is too late.
Why the Timing of This Data Matters
This study reviewed scans taken between 2021 and 2025. The protective pattern held up across several years of real-world care, not just a single snapshot. So this is not a fluke finding. It is a consistent signal that most bone health guidance still ignores.
Why Estrogen Is a Bone-Building Hormone, Not Just a Cycle Hormone
Estrogen slows the natural breakdown of old bone tissue and supports the cells that build new bone. When estrogen drops sharply at menopause, that balance tips hard toward breakdown, and bone density can decline fast in the years right after your last period.
I see this pattern constantly at Living Well Dallas. A woman gets her first bone density scan in her late 50s or 60s, years after the steepest decline already happened. Nobody suggested a baseline scan any earlier. By the time bone loss shows up on a scan, she has already lost her best window. That is when hormone therapy could have done the most good.
The Menopause Society recommends bone density screening at the start of menopause for women with risk factors. That is well before the standard screening age of 65. This guidance matters. New data shows hormone therapy works best as prevention, not as a fix after loss has already occurred.
What This Means for You
If you are approaching menopause or already past it, do not wait for a fracture to start the bone density conversation. Ask your doctor for a baseline DXA scan and a real discussion about hormone therapy. This matters especially if you have a family history of osteoporosis or fractures.
A personalized approach to hormone therapy bone density protection weighs your full risk profile: family history, current bone density, other heart and cancer risk factors, and your personal preferences. It is not a blanket policy that skips the conversation entirely. And because timing matters this much, starting that conversation in perimenopause, not a decade later, gives you the most protective window.
For women who want this kind of personalized bone health plan without an in-person visit, Menrva Health can help. It offers the same root-cause approach through telehealth in all 50 states.
Key Takeaways
- A 387-woman study presented at ENDO 2026 found hormone therapy users had a 69% lower risk of low bone mineral density than nonusers. The biggest gains showed up at the spine and hip.
- Only about a third of the women in the study were using hormone therapy, meaning most women in this cohort were missing a strongly protective option.
- Estrogen actively slows bone breakdown and supports new bone formation, so its decline at menopause directly speeds up bone loss, not just hot flashes and mood changes.
- Bone loss has no symptoms until a fracture occurs, making early screening and early conversations about hormone therapy more valuable than waiting for a diagnosis.
- A baseline bone density scan at the start of menopause, not at age 65, gives women and their doctors the clearest picture of their real risk.
Frequently Asked Questions
Does hormone therapy really protect against bone loss? Yes. A 2026 study of 387 women found that hormone therapy users had a 69% lower risk of low bone mineral density than women not using it. The strongest effect showed up at the spine and hip.
When should I start thinking about hormone therapy bone density protection? Ideally at the start of perimenopause, not after a scan already shows bone loss. Estrogen’s protective effect on bone works best as prevention rather than as a late-stage fix.
Getting Screened Early
When should I get my first bone density scan? Ask for a baseline DXA scan at the start of menopause if you have any risk factors. Do not wait until the standard screening age of 65. Specifically, a family history of osteoporosis or fractures should move that timeline up.
What counts as a risk factor for early bone loss? Family history of osteoporosis or fractures, early or premature menopause, smoking, and long-term steroid drug use all raise your risk. So do a small frame and low body weight, though those factors matter less than family history.
Is Hormone Therapy Bone Density Protection Right for You
Is hormone therapy safe for bone protection? For most women within ten years of menopause and without specific contraindications, hormone therapy carries a favorable risk profile for bone and overall health. This is especially true for transdermal forms. That decision should still be personalized with a doctor who knows your full history.
Where can I get a personalized bone health plan? In-person bone health workups are available at Living Well Dallas for patients in the Dallas area. Menrva Health offers the same personalized planning through telehealth in all 50 states.
Dr. Betty’s Bottom Line
I have watched too many women lose bone density quietly for a decade. Nobody brought up hormone therapy as a protective option, not just a hot flash treatment. This study puts a real number on what that silence costs. A 69% difference in risk is not something any doctor should leave out of the conversation.
Here’s what changes in my practice because of data like this. Every woman starting perimenopause gets a real conversation about bone health, including a baseline scan if she has any risk factors. We do not wait until she is 65 or already has a fracture. Because estrogen protects bone best as prevention, waiting for damage to show up on a scan means losing the window where treatment matters most.
You should not have to ask for this conversation twice. And you definitely should not have to wait for a fracture to have it at all. Your bones deserve the same root-cause attention as your hot flashes.
Ready to find YOUR root cause? In-person bone health care is available at Living Well Dallas for patients in the Dallas area. Menrva Health offers personalized hormone and bone health planning through telehealth in all 50 states.
Source: Espinoza-Peralta D, et al. Menopausal Hormone Therapy Is Associated with a 69% Lower Risk of Low Bone Mineral Density in Postmenopausal Women: A Retrospective Cohort Study. Presented at ENDO 2026, the Endocrine Society Annual Meeting; June 13-16, 2026; Chicago, IL. Abstract ORF34-05.